TAG:
clinical laboratory testing
Existing CLIA Language Drives PT Enforcement
By Joseph Burns | From the Volume XIX No. 11 – August 6, 2012 Issue
CEO SUMMARY: Revocation of a lab’s CLIA license as penalty for inadvertent errors in handling proficiency tests (PT) is not a new problem. As explained here, most clinical laboratories have appropriate protocols for handling PT samples. But, when errors occur, the Centers for Medicare &…
Employers, Payers Are Challenging ‘High’ Test Prices
By R. Lewis Dark | From the Volume XIX No. 10 – July 16, 2012 Issue
ONE NATIONAL TREND IN CLINICAL LABORATORY TESTING that has not yet gotten wide play outside the pages of THE DARK REPORT is the emergence of what might be termed a “war” by national and regional health insurers against the “higher” prices often charged by hospital laboratories. This is a key…
New BlueCard Policies Affect Lab Test Claims
By Joseph Burns | From the Volume XIX No. 10 – July 16, 2012 Issue
CEO SUMMARY: This new policy from the Blue Cross and Blue Shield Association (BCBSA) becomes effective on October 14, 2012. No longer can a local lab provide service to a member under the BlueCard program and be paid by the local plan in the region where the service was provided….
Lab Site Visits in NZ Show Impact of Lab Contracting
By Robert Michel | From the Volume XIX No. 10 – July 16, 2012 Issue
CEO SUMMARY: In some ways, the story of the New Zealand’s health system’s 15-year strategy to reduce the cost of clinical laboratory testing is a cautionary tale for public laboratory companies in the United States. During THE DARK REPORT’S site visit to several private labs in New …
Cleveland Clinic Lab Aims to Grow Reference Testing
By Joseph Burns | From the Volume XIX No. 8 – June 4, 2012 Issue
CEO SUMMARY: In the national market for reference and esoteric testing, Cleveland Clinic Laboratories (CCL) is preparing to expand its presence. It has just moved into a $75 million state-of-the-art laboratory facility and wants to increase its outreach reference testing by four-fold with…
Securing your Lab’s Success as Healthcare Reforms
By R. Lewis Dark | From the Volume XIX No. 5 – April 2, 2012 Issue
IT IS PROBABLY SAFE TO ASSUME THAT MOST OF YOU RECOGNIZE that the American healthcare system is about to undergo its most extensive transformation of the past 50 years. For better or for worse, we are about to see the end of medicine dominated by fee-for-service reimbursement and a fragmented deliver…
Payer Trend in New Hampshire Is to Engage Lab Patients
By Robert Michel | From the Volume XIX No. 5 – April 2, 2012 Issue
CEO SUMMARY: A health insurer’s two-year-old effort to have patients choose low-cost laboratory testing options is causing patients to shift their lab work away from New Hampshire’s hospitals and instead use Quest Diagnostics, LabCorp, and ConVerge (a commercial lab company). This new…
Today’s Lab Test Model Won’t Survive Reforms
By Robert Michel | From the Volume XIX No. 4 – March 12, 2012 Issue
CEO SUMMARY: For more than three decades, independent lab companies have waxed fat by increasing their respective market share of lab test referrals from office-based physicians. This era is poised to end as growing numbers of office-based physicians begin to practice medicine within an a…
Shaw & Adelman Successful Support of Lab Networks Need Hospital Leadership
By Joseph Burns | From the Volume XIX No. 3 – February 20, 2012 Issue
CEO Summary: In the second installment of our exclusive two- part interview, the executive directors of two regional laboratory networks formed in the 1990s (one in Michigan and one in Washington State) share their assessment of why their respective lab networks have performed strongly ov…
MedTox, Cleveland Clinic Labs, Apollo PACS, Dell, British Columbia Health
By Robert Michel | From the Volume XIX No. 3 – February 20, 2012 Issue
GENOME SEQUENCING TO BE OFFERED BY NORWAY IN NATIONAL HEALTH PLAN HERE’S A MILESTONE ON THE PATH TO PERSONALIZED MEDICINE. Norway is the first nation to announce that its national health system will incorporate whole genome sequencing. Cancer is the target of Norway’s f…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized